Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
International Journal of Molecular Sciences · 15.11.2026 · 27 (22) · 10225
DOI: 10.3390/ijms272210225 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.11.2026. Verfasst von Kayla R. Arroyo und 6 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Georgia State University.
Abstract (Originalsprache)
Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
Förderung
- Georgia State University
Zitieren
APA
Arroyo, K. R., Qian, S., Cho, H., Guan, X., Liu, Q., Darvishi, P., & Du, L. (2026). Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection. International Journal of Molecular Sciences, 27(22), 10225. https://doi.org/10.3390/ijms272210225
Vancouver
Arroyo KR, Qian S, Cho H, Guan X, Liu Q, Darvishi P, et al. Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection. International Journal of Molecular Sciences. 2026;27(22):10225. doi:10.3390/ijms272210225
BibTeX
@article{Arroyo2026,
author = {Arroyo, Kayla R. and Qian, Shengnan and Cho, Hansam and Guan, Xiaoqing and Liu, Qian and Darvishi, Parisa and Du, Lanying},
title = {Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10225},
doi = {10.3390/ijms272210225}
}
EUVIMED